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Abstract
Background: Immunosuppression is documented in several malignant diseases, including breast
cancer. Subsequently, future therapeutic concepts might include immunological approaches.
However, detailed knowledge about tumor immunogenicity and host immunoreactivity, and how
to assess these adequately, is still limited. We studied CD28 and CD3-ζ expression in sentinel node
biopsies (SNB) from breast cancer patients to analyze tumor-related changes in T cell activity.
Method: 25 women underwent surgery for primary breast cancer, including SNB. Frozen sections
from 21 sentinel nodes could be analyzed with a double-staining technique. CD28 expression was
studied in CD4+ and CD8+ T-lymphocyte subsets and compared with CD3-ζ expression in three
specified nodal regions.
Results: The degree of CD28 expression varied between the different lymph node areas. The
lowest degree of CD28 expression was observed in CD4+ T-lymphocytes in the paracortex and
germinal centers. Here, a good agreement with CD3-ζ expression was found. A higher CD28
expression was noted in CD4+ T-cells in the primary follicles, where concordance with CD3-ζ
expression was weaker. The CD8+ T-lymphocyte subset displayed generally a higher degree of
CD28 expression than the CD4+ subset.
Conclusion: Sentinel lymph nodes from breast cancer patients displayed local immunosuppression
of varying extent. In the areas with the lowest degree of CD28 expression an accordingly low CD3-
ζ expression was found. The SNB might prove an important diagnostic tool for the evaluation of
interactions between tumor and the host immune system, helping to select patients who might
benefit from adjuvant immunotherapy.
Background
Numerous studies [1] portray a decreased anti-tumor
immunoreactivity in patients with malignancies, includ-
ing breast cancer [2-4], and its correlation with disease
progression and survival [5,6]. Antigen presentation and
subsequent T-cell activation play a major role in initiating
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and maintaining an adequate anti-tumor response. How-
ever, the complex signaling cascades engaged in this proc-
ess are not yet fully understood, rendering it difficult to be
successfully addressed in therapeutical approaches. Better
knowledge of these mechanisms is therefore essential for
further development of immunological treatment
strategies.
The CD28 surface receptor is normally expressed on 95%
of CD4+ T-cells and approximately 50% of CD8+ T-cells
in human peripheral blood [7]. Its natural ligands, the B7
molecules, are found on various antigen-presenting cells
[8]. CD28 expression increases in activated T-cells [9].
Ligation of CD28 possesses major importance as a sec-
ond, co-stimulatory signal during antigen/MHC complex
presentation [10], hereby leading to a lower T-cell activa-
tion threshold and a longer duration of the proliferative
response [11]. However, activation via the T-cell receptor
alone induces transient T-cell proliferation [12], T-cell
anergy, or deletion [13].
Decreased CD28 expression is described in dysfunctional
peripheral T-lymphocytes from patients with hairy cell
leukemia [14] and chronic lymphocytic leukemia [15]. In
colorectal cancer, tumor-infiltrating lymphocytes (TIL)
lack CD28 in contrast to those in normal colon intersti-
tium [16]. This is consistent with findings in TIL from pri-
mary melanoma patients [17]. In melanoma metastases,
CD28 down-regulation is more pronounced in areas of
tumor regression [18,19]. Compared to healthy controls,
breast cancer patients display significantly lower percent-
ages of CD28+ T cells in peripheral blood [20]. To our
knowledge, no studies as to the expression of CD28 in
sentinel node biopsies from breast cancer patients have
yet been published.
The expression of the zeta chain of the T-cell receptor
(CD3-ζ) is decreased in sentinel node biopsies from
breast cancer patients [21]. This down-regulation is most
pronounced in the paracortex, the main T-cell activation
area. In the present study, CD28 expression was analyzed
in the same material and subsequently compared with
CD3-ζ expression in parallel sections.
Methods
Study population
The study comprised 25 patients who underwent surgery
for primary breast cancer, using the sentinel node biopsy
technique. Inclusion criteria for enrolment in the study
protocol were informed patient consent and a newly diag-
nosed palpable invasive breast cancer. Exclusion criteria
were palpable axillary metastases, multifocality of the can-
cer, ongoing pregnancy or preoperative cytotoxic
treatment.
In two cases, the sentinel node could not be immunolog-
ically analyzed due to lack of technical quality. In two
other cases, nodal tumor growth was too abundant and
remaining lymphoid tissue too little to analyze the sec-
tions. Thus, the remaining study population comprised
21 patients. Patient and tumor characteristics are pre-
sented in Table 1.
The study protocol was approved by the ethics commit-
tees at the University of Uppsala and the University Hos-
pital of Linköping.
Identification of sentinel node
Sentinel nodes were identified by injection of a radioac-
tive tracer (Tc-99-nanocolloid) close to the tumor site,
preoperative lymphoscintigrams, and injection of Patent
blue dye (Guerbet, Paris, France). After biopsy, the senti-
nel nodes were sent fresh to the pathology department.
Specimens were snap-frozen and tissue sections (6–7 µm
thick) were obtained for immediate diagnostic analysis
regarding the occurrence of metastasis in the sentinel
node. Additional frozen sections were wrapped in para-
film and stored at -70°C until processed further at Univer-
sity Hospital of Linköping. Routine diagnostic studies of
both tumor tissue and lymph nodes were performed at
the pathology department of Central Hospital, Västerås
and comprised all parameters listed in Table 1.
Monoclonal antibodies
The monoclonal antibodies used were as follows: CD4
(Clone SK3, Becton-Dickinson, Stockholm, Sweden),
CD8 (Clone SK1, Becton-Dickinson, Stockholm, Swe-
den), CD28 (Clone L293, Becton-Dickinson, Stockholm,
Sweden), CD3 (Clone UCHT1, DAKO Stockholm, Swe-
den), TCR-zeta (Clone 2H2D9 (TIA-2), Immunotech,
Stockholm, Sweden).
Preparation of node biopsies and immunological staining 
of tissue sections
Tissue sections obtained as described above were fixed
with 4% paraformaldehyde (pH 7.4) (Riedel-de Haen AG,
Seelze, Germany), supplemented with 5.4 g/L of glucose
for 5 min and soon afterward washed three times in
Hanks' balanced salt solution (BSS; Gibco, Paisley, United
Kingdom) supplemented with 0.01 M HEPES solution. To
avoid unspecific binding, sections were blocked with nor-
mal rabbit serum before the first staining and subse-
quently incubated with the primary antibodies CD3 (1/
40), CD4 (1/25) and CD8 (1/50) for 30 minutes. After the
slides had been washed in BSS/saponin, biotinylated rab-
bit anti-mouse immunoglobulin was added at a 1/100
dilution in BSS/saponin. Mouse IgG (Sigma, Stockholm,
Sweden) was used as a negative control. The slides were
then incubated with peroxidase-labeled streptavidine
(P0397; Dako, Stockholm, Sweden) at a 1/100 dilution inJournal of Translational Medicine 2004, 2:45 http://www.translational-medicine.com/content/2/1/45
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BSS/saponin for 30 minutes. DAB (3,3'-diaminobenzi-
dine, D-5637, Sigma, Stockholm, Sweden) was used as a
substrate, which resulted in a brown color. The expression
of the zeta chain or CD28 was identified using mouse
monoclonal antibodies to these substances. The sections
were first blocked by incubation with normal goat serum
and subsequently incubated with the primary antibodies.
Sections stained for the zeta chain (1/2.5) were incubated
for 30 minutes while sections stained for CD28 (1/25)
were incubated over night. The slides were again washed
in BSS/saponin and incubated with goat anti-mouse
immunoglobulin for 30 minutes and then with the alka-
line phosphatase-anti-alkaline phosphatase (APAAP)
mouse monoclonal antibody (Dakopatts D 651) at a dilu-
tion of 1/25 in BSS/saponin. After washes in BSS/saponin
and Tris-buffered saline (TBS) and incubation with the
alkaline phosphatase substrate (Naphthol AS-MX), 2 mg
phosphate (Sigma N4875), 0.2 ml dimethylformamide,
9.8 ml 0.1 M Tris buffer pH 8.2, 50 µl 1 M levamisole
(Sigma L-9756) and 10 mg Fast-Red TR salt (Sigma F
1500) for 20 minutes, the sections were again washed in
TBS. Thereafter, the sections were counterstained in
Mayer's haematoxylin for 15 minutes and mounted in
Glycergel (Dakopatts, Sweden). All antibody solutions
contained 2% normal blood donor AB serum and all
incubations were performed in a moist chamber. The
APAAP technique resulted in bright red staining for CD3-
ζ and CD28. Double-stained cells appeared as red-brown;
those with down-regulated CD3-ζ or CD28 were domi-
nated by a brown color.
Evaluation of occurrence and distribution of CD28
Two independent investigators (A.H., B.G.) analyzed
whole sections of the sentinel nodes. The degree of CD28
expression was evaluated in both CD4+ and CD8+ T-cell
subsets within three lymph node areas: primary follicles,
secondary follicles (germinal centers) and paracortex. The
number of CD4+ and CD8+ T-lymphocytes expressing
Table 1: Tumor and other selected characteristics of 21 women operated on for primary breast cancer.
Median (range) n (%)
Age 60 (36–86)
Menopausal status
premenopausal 5 (24)
postmenopausal 16 (76)
Nodal status
negative SNB 12 (57)
positive SNB 9 (43)
only positive SNB 7 (33)
3–4 positive lymph nodes 2 (10)
Tumor stage
I 7 (33)
IIa 7 (33)
IIb 7 (33)
Histological type
ductal invasive 17 (81)
lobular 3 (14)
mucinous 1 (5)
Tumor size (mm) 21 (1–60)
Estrogen receptor status
positive 19 (90)
negative 2 (10)
DNA ploidy status
euploid 9 (43)
aneuploid 12 (57)
S phase
high 3 (14)
low 18 (86)
(Elston) histological grade
I 2 (10)
II 11 (52)
III 7 (33)
Not measured 1 (5)
SNB = sentinel node biopsyJournal of Translational Medicine 2004, 2:45 http://www.translational-medicine.com/content/2/1/45
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CD28 was semiquantitatively scored as "high" (>75%
CD28+), "moderate" (50–75% CD28+) and "low" (<50%
CD28+). The regional scores were then put into correla-
tion with our earlier data on expression of CD3-ζ in par-
allel sections of the same patients where the same scoring
system was applied [21]. There was good agreement
between the scores of the two investigators (80%). The
few discrepancies between scores were discussed and the
reasons for the difference in the scores could be identified.
Thus, a consensus regarding the proper evaluation could
always be reached.
Statistical analysis
For testing correlations between the patient data depicted
in Table 1 and expression of CD28 and CD3-ζ, the Mann-
Whitney U test was used. The Kruskal-Wallis test was
applied for comparing the three analyzed lymph node
regions regarding the expression of the respective markers
and for the comparison of CD28 expression in the T-cell
subgroups (CD4+ and CD8+) within the same lymph
node region. A p-value less than 0.05 was considered sig-
nificant. For testing the agreement between the expression
of CD28 (in the two separate T-cell subsets) and the
expression of CD3-ζ for every nodal area separately, the
Prevalence-Adjusted Bias-Adjusted Kappa (PABAK) was
used. It has the same interpretation as Cohen's Kappa
[22]. A value of >0.80 indicates excellent agreement,
0.61–0.80 good agreement, 0.41–0.60 moderate agree-
ment, 0.21–0.40 fair and 0.00–0.20 poor agreement. Val-
ues less than zero suggest that the agreement is worse than
expected by chance.
Results
Expression of CD28
The degree of CD28 expression varied considerably, both
between individual patients and between different
regions of the sentinel lymph nodes. The lowest degree of
CD28 expression was seen in CD4+ T-lymphocytes
located in the paracortex and the secondary follicles.
CD8+ T-lymphocytes displayed a significantly higher
degree of CD28 expression than CD4+ T-cells in both
paracortex (p < 0.001) and primary follicles (p < 0.001).
There were statistically significant differences in CD28
expression in CD4+ T-cells comparing the three nodal
regions (p < 0.01), with CD28 expression being higher in
primary follicles than in secondary follicles and paracor-
tex. No such differences were found analyzing CD28
expression in CD8+ T-lymphocytes. No significant corre-
lation could be found between the degree of CD28 expres-
sion and tumor size, histological type, hormone receptor
status, DNA ploidy status, Elston histological grade, S-
phase, patient age, nodal status or tumor stage following
the TNM classification of malignant tumors, neither were
there any significant correlation detected regarding clini-
cal data and the degree of CD3-ζ expression in our previ-
ously published material [21].
Primary follicles
Primary follicles are cortical lymph node areas housing
predominantly B-lymphocytes. The analysis could be per-
formed in 20 cases. In the CD4+ subset (Table 2), 7 of 20
patients displayed a high degree of CD28 expression (Fig-
ure 1a), 5 of 20 a moderate and 8 of 20 a low degree of
CD28 expression (Figure 1b).
In the CD8+ subset of T-lymphocytes (Table 3), a high
degree of CD28 expression was found in all cases except
two, which displayed a moderate degree.
Germinal centers
These B-cell areas, which develop as secondary follicles
upon antigenic stimulation, could be analyzed in 16
patients. In the remaining five cases, no or very few germi-
nal centers were found. In the CD4+ subset (Table 2), 4 of
16 patients exhibited a high or moderate degree of CD28
expression (Figure 1c), and 12 of 16 a low degree (Figure
1d). The small numbers of CD8+ T-lymphocytes in this
compartment did not permit immunological analysis in
any of the cases.
Paracortex
A markedly low expression of CD28 was observed in the
paracortex, the principal T-cell activation area. Sections of
20 sentinel nodes could be analyzed. In the CD4+ subset
(Table 2), none of the cases established a high CD28
expression, while it was moderate in 5 of 20 patients (Fig-
ure 1e), and low in 15 (Figure 1f). In contrast, 15 of 21
cases displayed a high CD28 expression in the CD8+ sub-
set, 5 of 21 cases a moderate, and only one case a low
CD28 expression (Table 3).
Comparison between CD28 and CD3-ζ expression
As described in a previous paper of our group [21], a low
expression of CD3-ζ was seen in the primary follicles in 6
of 24 patients, in the germinal centers in 13 of 18 patients
and in the paracortex in 19 of 24 patients. In the present
Table 2: Degree of CD28 expression in the CD4+ T-lymphocyte 
subset in different areas of the sentinel nodes from 21 breast 
cancer patients (numbers are frequencies).
Expression of CD28 on CD4+
High Moderate Low
Primary follicles 758
Secondary follicles 13 1 2
Paracortex 05 1 5Journal of Translational Medicine 2004, 2:45 http://www.translational-medicine.com/content/2/1/45
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Double staining of a sentinel node for CD4 (brown staining) and CD28 (red staining) Figure 1
Double staining of a sentinel node for CD4 (brown staining) and CD28 (red staining).1a). Primary follicle showing a high 
expression of CD28.1b). Primary follicle showing a low expression of CD28. 1c). Germinal center showing a moderate 
expression of CD28. 1d). Germinal center showing a low expression of CD28. 1e). Paracortical area showing a moderate 
expression of CD28. 1f). Paracortical area showing a low expression of CD28. 1g). Double staining of a sentinel node for 
CD3 (brown  staining) and the zeta chain (red staining).  Paracortical area showing a low expression of the zeta  chain. 1h). 
Double staining of a sentinel node for CD8 (brown  staining) and CD28 (red staining). Corresponding  paracortical area show-
ing a high expression of CD28.  Journal of Translational Medicine 2004, 2:45 http://www.translational-medicine.com/content/2/1/45
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study, the expression of CD28 was analyzed in parallel
sections from the same patients.
The expression of CD28 and CD3-ζ was always compared
in the same area of the same lymph node. Degrees of
expression were only considered corresponding if a
patient displayed exactly the same degree of expression
(i.e. low, moderate or high) of both markers in that area.
In primary follicles, corresponding degrees of expression
were found in 12 of 20 patients analyzing the CD4+ sub-
set (Table 4), with a PABAK value of 0.40. Nevertheless,
some sentinel node biopsies with a high CD3-ζ expres-
sion indicated a low (n = 3) or moderate (n = 3) CD28
expression on CD4+ T-cells. This discrepancy is hardly
due to the presence of CD8+ T-cells as these cells pre-
sented a low or moderate CD28 expression in only one of
these six biopsies. In the CD8+ subset, only 10 of 21
patients showed corresponding degrees (Table 7), result-
ing in a PABAK value of 0.21.
In secondary follicles, 11 of 15 patients had the same
degrees of CD28 and CD3-ζ in the CD4+ subset (Table 5),
corresponding a PABAK value of 0.60. As earlier men-
tioned, the CD8+ subset was excluded from immunologi-
cal analysis in this area due to the small numbers of CD8+
T-cells present.
In the paracortex, the degree of CD28 and CD3-ζ expres-
sion was corresponding in 15 of 20 cases in the CD4+ sub-
set (Table 6). Here, the highest PABAK was observed,
reaching a value of 0.62. As the vast majority of T-lym-
phocytes in the paracortex belonged to the CD4+ subset,
the expression of the zeta chain by CD3+ T-cells actually
represented the expression by CD4+ lymphocytes. In the
CD8+ subset, only 2 of 21 patients displayed correspond-
ing degrees (Table 8), leading to a PABAK value of -0.36.
Instead, 11 patients with a low degree of CD3-ζ expres-
sion (figure 1g) showed a high CD28 expression in paral-
lel sections (figure 1h).
Table 3: Degree of CD28 expression in the CD8+ T-lymphocyte 
subset in different areas of the sentinel nodes from 21 breast 
cancer patients (numbers are frequencies).
Expression of CD28 on CD8+
High Moderate Low
Primary follicles 19 2 0
Paracortex 15 5 1
Table 4: Degree of CD28 expression on CD4+ T-lymphocytes in 
comparison with CD3-ζ expression in primary follicles. The table 
comprises 20 cases, where both analyses could be done in the 
same sentinel node biopsies (numbers are frequencies).
Expression of CD3-ζ Expression of CD28 on CD4+
High Moderate Low
High 533
Moderate 120
Low 105
Table 5: Degree of CD28 expression on CD4+ T-lymphocytes in 
comparison with CD3-ζ expression in secondary follicles 
(germinal centers). The table comprises 15 cases, where both 
analyses could be done in the same sentinel node biopsies 
(numbers are frequencies).
Expression of CD3-ζ Expression of CD28 on CD4+
High Moderate Low
High 011
Moderate 011
Low 01 1 0
Table 6: Degree of CD28 expression on CD4+ T-lymphocytes in 
comparison with CD3-ζ expression in the paracortex. The table 
comprises 20 cases, where both analyses could be done in the 
same sentinel node biopsies (numbers are frequencies).
Expression of CD3-ζ Expression of CD28 on CD4+
High Moderate Low
High 001
Moderate 021
Low 03 1 3
Table 7: Degree of CD28 expression on CD8+ T-lymphocytes in 
comparison with CD3-ζ expression in the primary follicles. 
Parallel sections of all 21 sentinel node biopsies were analyzed 
(numbers are frequencies).
Expression of CD3-ζ Expression of CD28 on CD8+
High Moderate Low
High 10 1 0
Moderate 400
Low 510Journal of Translational Medicine 2004, 2:45 http://www.translational-medicine.com/content/2/1/45
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Discussion
CD28 expression was studied in CD4+ and CD8+ T-lym-
phocyte subsets and compared with CD3-ζ expression in
sentinel node biopsies from breast cancer patients. The
lowest expression of CD28 was found in the CD4+ subset
in the paracortex and germinal centers. In these areas, a
moderate to good agreement between expression of CD28
on CD4+ T-cells and expression of CD3-ζ was observed.
In the primary follicles, where CD28 expression on CD4+
T-cells was higher, the concordance between the two
markers was less pronounced.
The CD8+ subset of T-lymphocytes displayed generally a
higher degree of CD28 expression than the CD4+ subset.
This applied for all analyzed regions of the lymph nodes.
Moreover, the congruence with CD3-ζ expression was
weaker than in the CD4+ subset.
The different functions of CD4+ and CD8+ T lymphocyte
subsets are well documented. Some investigators suggest
that CD8+ T-lymphocytes be closer connected to the
CD28/B7 pathway than CD4+ T-cells [23]. Moreover,
higher levels of B7 seem to be necessary to evoke an acti-
vation of CD8+ T-cells equivalent to CD4+ T-cells [24].
CD8+ T-cells from HIV positive individuals illustrate a
more pronounced CD28 down-regulation than CD4+ T-
cells, and their weakened proliferative response is marked
by decreased Ca influx [25]. The presented data show a
higher CD28 expression in CD8+ than in CD4+ T-cells,
which stands in contrast to findings described in periph-
eral blood from healthy donors [7]. Thus, our results
might suggest altered functions of CD4+ and CD8+ T-
lymphocytes in the context of anti-tumor
immunoreactivity.
It was proposed that T-lymphocytes from secondary lym-
phoid organs, rather than from peripheral blood, should
be used to assess host immunoreactivity [26]. In bone
marrow-derived T-cells from breast cancer patients,
immunological changes are more pronounced than in
peripheral blood lymphocytes [27,28]. Several studies
document decreased CD28 and CD3-ζ expression in
peripheral blood from breast cancer patients [2,4,20] in
comparison to healthy individuals. However, there are no
immunological data from axillary sentinel lymph nodes
from normal controls. Even if such data would be most
valuable in the interpretation of the present findings, it
seems ethically unjustifiable to obtain such material. Still,
the sentinel node biopsy might be the method of choice
for assessing early immunological alterations in that the
host immune response against tumors is initiated here. To
confirm its distinct key position, future studies should
include the comparative analysis of non-sentinel axillary
lymph nodes in a distance-dependent fashion. In the
present study, the down-regulation of CD28 and CD3-ζ
clearly seems to be more accentuated in sentinel node
biopsies than otherwise described in breast cancer
patients.
Induction of T-cell anergy is one of the major tumor
escape mechanisms [1], and its abrogation is therefore a
main focus in the development of immunological anti-
cancer strategies. Co-stimulation via the CD28/B7 path-
way can prevent the induction of anergy in T-cell clones
[29], but it is assumed that this might not be sufficient to
reverse T-cell anergy once it is established [30]. Addition
of exogenous IL-2 promotes reversal of T-cell anergy in
this situation [31]. It was even suggested that decreased
CD28 expression might be the result of continuous anti-
genic stimulation, aiming at reconstituting the non-
responsiveness of T-cells [32]. The high numbers of
CD4+/CD28- T-cells found in patients with rheumatoid
arthritis are consistent with this theory [33]. Thus, the
functional significance of decreased CD28 expression
remains complex to interpret.
The functions of CD28 and CD3-ζ might be closely linked
together. Engineered T-cells co-delivering CD28 activa-
tion in addition to the T-cell receptor (TCR) subunit CD3-
ζ are more effective to activate an anti-tumor response in
vivo than T-cells with TCR-CD3-ζ only [34]. Without co-
stimulatory signaling via CD28/B7, tyrosine phosphoryla-
tion of the zeta chain of the T-cell receptor is inhibited
[35]. Moreover, signaling via CD3-ζ could activate pro-
tein-tyrosine kinases that subsequently augment signal
transduction via CD28/B7 [36]. The present data docu-
ment a good agreement in the expression of the two mark-
ers in areas of pronounced down-regulation.
Several studies point towards a role for immunological
treatment approaches in breast cancer [37-39]. The
present data on decreased expression of CD28 and CD3-ζ
in sentinel lymph nodes confirm that breast cancer has an
impact on local immunoreactivity. However, the occur-
rence of varying individual patterns could be explained by
the existence of both non-immunogenic and immuno-
Table 8: Degree of CD28 expression on CD8+ T-lymphocytes in 
comparison with CD3-ζ expression in the paracortex. Parallel 
sections of all 21 sentinel node biopsies were analyzed (numbers 
are frequencies).
Expression of CD3-ζ Expression of CD28 on CD8+
High Moderate Low
High 100
Moderate 300
Low 11 5 1Journal of Translational Medicine 2004, 2:45 http://www.translational-medicine.com/content/2/1/45
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genic, if not immunotoxic tumor types. Tumors with little
inherent immunogenicity might not be as susceptible to
immunotherapy as immunogenic tumor types [40].
Therefore, the decision whether to include immuno-
therapy in a treatment could be facilitated by analyzing
the individual patient's immunological anti-tumor
response. In this context, the sentinel node biopsy offers a
unique opportunity to study early indicators of host-
tumor interaction, and contributes valuable information
for further conception and development of immunologi-
cal treatment strategies.
Conclusions
The axillary lymph node status is of utmost importance
for breast cancer prognosis and the choice of adequate
adjuvant treatment. Today, the sentinel node biopsy tech-
nique is widely used as a diagnostic tool to gain that valu-
able information while limiting the operative procedure
to a necessary minimum. However, it is also in the
sentinel node that the immunoreactivity against the
tumor is initiated.
In this study, a varying extent of immunosuppression was
observed, represented by a decreased expression of CD28
and CD3-ζ in certain areas of the lymph node. The con-
cordance between both markers was highest in the areas
of most pronounced down-regulation, namely the para-
cortical region and the germinal centers. As immunologi-
cal reactivity was not distributed evenly over the different
areas of the lymph node, this might illustrate the dynamic
nature of the immunological response to malignant dis-
ease within the complex functional anatomy of the lymph
node. Thus, the immunohistochemical analysis of the
sentinel node biopsy with respect to its preserved architec-
ture might prove an important instrument for the evalua-
tion of interactions between the tumor and the host
immune system, helping to select patients who might
benefit from adjuvant immunotherapy.
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